Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells

Cancer Research

Volumn 64, Issue 24, 2004, Pages 9115-9123

  Hui, Ai Min ^a   Zhang, Wei ^a   Chen, Wei ^a   Xi, Dan ^a   Purow, Benjamin ^a   Friedman, Glenn C ^b   Fine, Howard A ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CELGENE CORPORATION   (United States)

^c Bloch Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; CC 8490; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; FLOW CYTOMETRY; GENE; GENE EXPRESSION PROFILING; GLIOMA; HUMAN; HUMAN CELL; IEX 3 GENE; IL6 GENE; IL8 GENE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SECOND MESSENGER; SOD2 GENE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOPYRANS; BRAIN NEOPLASMS; CALCIUM; CELL LINE, TUMOR; DRUG SYNERGISM; ESTROGEN RECEPTOR MODULATORS; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE C; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 10844232874     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2740     Document Type: Article

References (59)

1. Goldenberg GJ, Froese EK. Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vivo. Cancer Res 1982;42:5147-51.
2. Gelmann EP. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? J Natl Cancer Inst (Bethesda) 1996;88:224-6.
3. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997;24:SI-65-70.
4. Pollack IF, Randall MS, Kristofit MP, et al. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 1990;50:7134-8.
5. Zhang W, Couldwell WT, Song H, et al. Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. Cancer Res 2000;60:5395-400.
6. Vertosick FT, Selker RG, Pollack IF, Arena V. The treatment of intracranial malignant glioma using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery 1992;30:897-903.
7. Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin-Cancer Res 1996;2:619-22.
8. Cloughesy TF, Woods RP, Black KL, et al. Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. J Neuro-Oncol 1997;35:39-45.
9. Mastronardi L, Puzzili F, Couldwell WT, Farah JM, Lunardi P. Tamoxifen and carboplatin combinational treatment of high-grade gliomas: results of a clinical trial on newly diagnosed patients. J Neuro-Oncol 1998;38:59-68.
10. Brandes AA, Ermani M, Turazzi S, et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 1999;17:645-50.
11. McKie JA, Bhagwat SS, Brady H, et al. Lead identification of a potent benzopyranone selective estrogen receptor modulator. Bioorg Med Chem Lett 2004;14:3407-10.
12. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997;3:437-42.
13. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced Taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001;61:4971-3.
14. Lau K-M, LaSpina M, Long J, Ho S-M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:3175-82.
15. Clapham DE. Calcium signaling. Cell 1995;80:259-68.
16. Berridge MJ. Neuronal calcium signaling. Neuron 1998;21:13-26.
17. Rizzuto R, Pinton P, Ferrari D, et al. Calcium and apoptosis: facts and hypotheses. Oncogene 2003;22:8619-27.
18. Yamamura M, Amano Y, Sakagami H, et al. Calcium mobilization during nicotine-induced cell death in human glioma and glioblastoma cell lines. Anticancer Res 1998;18:2499-502.
19. Wernyj RP, Mattson MP, Christakos S. Expression of calbindin-D28k in C6 glial cells stabilizes intracellular calcium levels and protects against apoptosis induced by calcium ionophore and amyloid beta-peptide. Mol Brain Res 1999;64:69-79.
20. Liu Z, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996;87:565-76.
21. Beg AA, Baltimore D. An essential role of NF-kappaB in preventing TNF-alpha-induced cell death. Science (Wash DC) 1996;274:782-4.
22. Wang C-Y, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (Wash DC) 1996;274:784-7.
23. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (Wash DC) 1996;274:787-9.
24. + T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med 2002;197:861-74.
25. Foo SY, Nolan GP. NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet 1999;15:229-35.
26. Kaltschmidt B, Kaltschmidt C, Hofmann TG, et al. The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur J Biochem 2000;267:3828-35.
27. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kappaB in p53-mediated programmed cell death. Nature (Lond) 2000;404:892-7.
28. Ivanov VN, Lee RK, Podack ER, Malek TR. Regulation of Fas-dependent activation-induced T cell apoptosis by camp signaling: a potential role for transcription factor NF-kappaB. Oncogene 1997;14:2455-64.
29. Hettmann T, DiDonato J, Karin M, Leiden JM. An essential role for nuclear factor kappaB in promoting double positive thymocyte apoptosis. J Exp Med 1999;189:145-57.
30. Bessho R, Matsubara K, Kubota M, et al. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappaB (NF-kappaB) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem Pharmacol 1994;48:1883-9.
31. Abbadie C, Kabrun N, Bouali F, et al. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell 1993;75:899-912.
32. Wu MX, Ao Z, Prasad KVS, Wu R, Schlossman S. F. IEX-IL, an apoptotic inhibitor involved in NF-kappaB-mediated cell survival. Science (Wash DC) 1998;281:998-1001.
33. De Keulenaer GW, Wang Y, Feng Y, et al. Identification of IEX-1 as a biomechanically controlled nuclear factor-kappaB target gene that inhibits cardiomyocyte hypertrophy. Circ Res 2002;90:690-6.
34. Zhang Y, Schlossman SF, Edwards RA, et al. Impaired apoptosis, extended duration of immune response, and a lupus-like autoimmune diseases in IEX-1-transgenic mice. Proc Natl Acad Sci USA 2002;99:878-83.
35. Xu Y, Kiningham KK, Devalaraja MN, et al. An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol 1999;18:709-22.
36. Kiningham KK, Xu Y, Daosukho C, Popova B, St Clair DK. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. Biochem J 2001;353:147-56.
37. Yi M-J, Park S-H, Cho H-N, et al. Heat-shock protein 25 (Hspb1) regulates manganes superoxide dismutase through activation of Nfkb (NF-kappaB). Radiat Res 2002;158:641-9.
38. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappaB transcription factor. Mol Cell Biol 1990;10:2327-34.
39. Brach MA, Gruss HJ, Kaisho T, et al. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kappaB. J Biol Chem 1993;268:8466-72.
40. An J, Sun Y, Sun R, Bettig MB. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene 2003;22:3371-85.
41. Kunsch C, Rosen CA. NF-kappaB subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 1993;13:6137-46.
42. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff KJ. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 1997;159:4952-8.
43. Osawa Y, Nagaki M, Banno Y, et al. Tumor necrosis factor alpha-induced interleukin-8 production via NF-kappaB and phosphatidylinositol 3-kinase/Akt pathways inhibits cell apoptosis in human hepatocytes. Infect Immun 2002;70:6294-301.
44. Mayo MW, Wang C-Y, Cogswell PC, et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogene Ras. Science (Wash DC) 1997;278:1812-5.
45. Wang C-Y, Cusack JC, Liu R, Maldwin AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-7.
46. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappaB. Nature (Lond) 1995;376:167-70.
47. Pierce JW, Ma R, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-aipha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996;156:3961-9.
48. Grilli M, Pizzi M, Memo M, Spano PF. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science (Wash DC) 1996;274:1383-5.
49. Pearce LL, Epperly MW, Greenberger JS, Pitt BR, Peterson J. Identification of respiratory complexes I and III as mitochondrial sites of damage following exposure to ionizing radiation and nitric oxide. Nitric Oxide: Biol Chem 2001;5:128-36.
50. Epperly MW, Sikora CA, DeFilippi SJ, et al. Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res 2002;157:568-77.
51. Drane P, Bravard A, Bouvard V, May E. Reciprocal down-regulation of p53 and SOD2 gene expression: implication in p53 mediated apoptosis. Oncogene 2001;20:430-9.
52. Zhao Y, Oberley TD, Chaiswing L, et al. Manganese superoxide dismutase deficiency enhances cell turnover via tumor promotor-induced alterations in AP-1 and p53-mediated pathways in a skin cancer model. Oncogene 2002;21:3836-46.
53. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond) 1991;352:345-7.
54. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997;89:227-34.
55. Hardin J, Macleod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994;84:3063-70.
56. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000;275:27845-50.
57. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3360-76.
58. Dunican AL, Leuenroth SJ, Grutkoski P, Ayala A, Simms HH. TNF-alpha-induced suppression of PMN apoptosis is mediated through interleukin-8 production. Shock 2000;14:284-9.
59. Abdollahi T, Robertson NM, Abdollahi A, Litwack G. Identification of interleukin-8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Cancer Res 2003;63:4521-6.